155 related articles for article (PubMed ID: 38242940)
21. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
22. Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma.
Ma Y; Chen X; Wang A; Zhao H; Lin Q; Bao H; Zhang Y; Hong S; Tang W; Huang Y; Yang Y; Wu X; Shao Y; Fang W; Zhang L
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737344
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Anti-PD1 Blockade in Treating Recurrent or Metastatic Nasopharyngeal Cancer: A Systematic Review and Meta-analysis.
Yeo BSY; Song HJJMD; Soong YL; Chua MLK; Ang MK; Lim DWT; See A; Lim CM
Oral Oncol; 2023 Jan; 136():106242. PubMed ID: 36413976
[TBL] [Abstract][Full Text] [Related]
24. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
[TBL] [Abstract][Full Text] [Related]
25. First-line chemotherapy or in combination with programmed cell death protein-1 antibody in patients with metastatic or recurrent biliary tract cancer.
Zhao S; Guo XG; Zhang D; Zhou G; Song P; Yang J; Zhang Y; Li P; Hu Y; Wang P
J Gastroenterol Hepatol; 2021 Dec; 36(12):3541-3547. PubMed ID: 34423859
[TBL] [Abstract][Full Text] [Related]
26. The efficacy of locoregional radiotherapy plus chemotherapy vs. chemotherapy alone in metastatic nasopharyngeal carcinoma: a meta-analysis.
Wang G; Shen L
Ann Palliat Med; 2021 Mar; 10(3):2584-2595. PubMed ID: 33474951
[TBL] [Abstract][Full Text] [Related]
27. Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study.
Lu Y; Huang H; Yang H; Hu X; Liu M; Huang C; Feng X; Chen X; Jiang Z
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4327-4338. PubMed ID: 36075994
[TBL] [Abstract][Full Text] [Related]
28. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wei Z; Zhang Z; Luo J; Li N; Peng X
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
[TBL] [Abstract][Full Text] [Related]
29. Assessment of Response to Different Induction Chemotherapy Regimens in Locally Advanced Nasopharyngeal Carcinoma.
Lian CL; Zhou R; Zhou Y; Zhou P; Wu SG
Drug Des Devel Ther; 2023; 17():551-562. PubMed ID: 36855516
[TBL] [Abstract][Full Text] [Related]
30. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
[TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma.
Li Y; Ji Y; Shen L; Yin X; Huang T; Deng B; Guo H; Wu Y; Chen Y
Front Oncol; 2022; 12():1015302. PubMed ID: 36605427
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
Masterson L; Howard J; Gonzalez-Cruz J; Jackson C; Barnett C; Overton L; Liu H; Ladwa R; Simpson F; McGrath M; Wallwork B; Jones T; Ottensmeier C; Chua MLK; Perry C; Khanna R; Panizza B; Porceddu S; Lechner M
Int J Cancer; 2020 Apr; 146(8):2305-2314. PubMed ID: 31950498
[TBL] [Abstract][Full Text] [Related]
33. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response.
Liu SL; Sun XS; Yan JJ; Chen QY; Lin HX; Wen YF; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Li XY; Lin C; Du YY; Yang ZC; Xiao BB; Yang JH; Tang LQ; Guo L; Mai HQ
Radiother Oncol; 2019 Aug; 137():83-94. PubMed ID: 31078941
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of VEGF/VEGFR inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A meta-analysis.
Xue S; Song G; Zhu Y; Zhang N; Tan Y
Oral Oncol; 2022 Dec; 135():106231. PubMed ID: 36327674
[TBL] [Abstract][Full Text] [Related]
36. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
37. A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (≥2 lines) anti-programmed death-1 monotherapy.
Li SC; Deng SW; Sun XS; Lan KQ; Guo CY; Lin DF; Liu LT; Liu SL; Mai HQ; Tang LQ
Oral Oncol; 2023 Apr; 139():106336. PubMed ID: 36827901
[TBL] [Abstract][Full Text] [Related]
38. Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
Kua VF; Ismail F; Chee Ee Phua V; Aslan NM
Asian Pac J Cancer Prev; 2013; 14(2):1121-6. PubMed ID: 23621198
[TBL] [Abstract][Full Text] [Related]
39. The safety and efficacy of gemcitabine and cisplatin (GP)-based induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
Tang M; Jia Z; Zhang J
Eur Arch Otorhinolaryngol; 2022 Mar; 279(3):1561-1572. PubMed ID: 34259896
[TBL] [Abstract][Full Text] [Related]
40. Predictive and prognostic role of early apolipoprotein A-I alteration in recurrent or metastatic nasopharyngeal carcinoma patients treated with anti-PD-1 therapy.
Xiao BJ; Sima XX; Chen G; Gulizeba H; Zhou T; Huang Y
Cancer Med; 2023 Aug; 12(16):16918-16928. PubMed ID: 37409613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
